USPTO serial 88278750
NEUWAY
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 31, 2021
- Examiner
- MIZELLE HOWARD, DEZMONA JULYE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with NEUWAY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,446*
Plus Government fees of $1,300
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
LEIGH ANN LINDQUIST
LEIGH ANN LINDQUIST SUGHRUE MION, PLLC2000 PENNSYLVANIA AVENUE NW, SUITE 9000WASHINGTON, DC 20006UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical, biological, biochemical and biotechnological products and preparations, namely small molecules, biologics, nucleic acids, proteins, lipids, polysaccharides, enzymes, antibodies, cells, microorganisms as well as fragments, fractions and derivatives thereof for laboratory or research use and manufacturing use | ACTIVE | — |
| 005 | Chemical, biological, biochemical and biotechnological products and preparations for medical, veterinary and pharmaceutical purposes, for the prevention and treatment of neurological, neurodegenerative, psychiatric, immune system related, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, urological, gynecological, reproductive, oncological, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, dermatological, lymphatic, inflammatory, infectious, hematological, renal, genetic, bacterial and viral diseases, sexual dysfunction and pain as well as for gene therapy, vaccination or immunostimmulation, namely small molecules, biologics, nucleic acids, proteins, lipids, polysaccharides, enzymes, antibodies, cells, microorganisms as well as fragments, fractions and derivatives thereof; diagnostic preparations for medical and veterinary use; medicinal preparations, pharmaceutical preparations and pharmaceutical substances for the prevention and treatment of neurological, neurodegenerative, psychiatric, immune system related, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, urological, gynecological, reproductive, oncological, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, dermatological, lymphatic, inflammatory, infectious, hematological, renal, genetic, bacterial and viral diseases, sexual dysfunction and pain as well as for gene therapy, vaccination or immunostimmulation; vaccines; adjuvants, carriers for active ingredients, drug delivery systems comprising protein based capsids or particles for the release of therapeutic or diagnostic agents for medical use in humans or animals; biological implants comprising active ingredients; drug delivery systems consisting of proteins in the form of capsids or particles; drug delivery systems comprising protein based capsids or particles for the release of therapeutic or diagnostic agents | ACTIVE | — |
| 040 | Manufacture of pharmaceutical products, medicinal products, medicaments from pharmaceutical compositions for third parties | ACTIVE | — |
| 042 | Scientific research and development for others, in particular in the fields of medicine, pharmacy, diagnostics, chemistry, biology, biochemistry and biotechnology; scientific research and development as well as biotechnological services with regard to manufacturing pharmaceutical preparations, active substance carriers, active substance transport systems, drug delivery systems and active substance implants for use on humans or animals, for others; development of pharmaceutical preparations, namely, medical products for the prevention and treatment of neurological, neurodegenerative, psychiatric, immune system related, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, urological, gynecological, reproductive, oncological, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, dermatological, lymphatic, inflammatory, infectious, hematological, renal, genetic, bacterial and viral diseases, sexual dysfunction and pain as well as for gene therapy, vaccination or immunostimmulation, for others | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by NEUWAY Pharma GmbH
- Other trademarks owned by NEUWAY Pharma GmbH
- Other trademarks owned by NEUWAY Pharma GmbH
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named NEUWAY
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 31, 2026 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Aug 31, 2026 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Aug 31, 2026 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Apr 26, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Apr 26, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 26, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 26, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 26, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Aug 31, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 27, 2021 | DP1B | 1(B) BASIS DELETED; PROCEED TO REGISTRATION | — |
| Jul 22, 2021 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jul 1, 2021 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Jul 1, 2021 | D1BR | TEAS DELETE 1(B) BASIS RECEIVED | — |
| Jun 22, 2021 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Apr 27, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 27, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 7, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 18, 2021 | OTHE | CASE RETURNED TO EXAMINATION | — |
| Mar 18, 2021 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Oct 30, 2020 | PCBG | PETITION TO DIRECTOR - CHANGE BASIS - GRANTED | — |
| Oct 29, 2020 | APET | ASSIGNED TO PETITION STAFF | — |
| Sep 26, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 24, 2020 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Sep 24, 2020 | EXT2 | SOU EXTENSION 2 FILED | — |
| Sep 24, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 11, 2020 | TPAD | TEAS PETITION TO AMEND BASIS RECEIVED | — |
| Mar 25, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 23, 2020 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Mar 23, 2020 | EXT1 | SOU EXTENSION 1 FILED | — |
| Mar 23, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 20, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 20, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 20, 2020 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Mar 20, 2020 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Mar 20, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 20, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 20, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Sep 24, 2019 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jul 30, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 30, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 10, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 24, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 21, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 21, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 21, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 12, 2019 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 12, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 12, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 12, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 9, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 25, 2019 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Feb 21, 2019 | ALIE | ASSIGNED TO LIE | — |
| Feb 20, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 14, 2019 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Jan 31, 2019 | NWAP | NEW APPLICATION ENTERED | — |